Amy B. Criego, MD, MS
Medical Director of International Diabetes Center and Department Chair of Park Nicollet Pediatric Endocrinology

About

Education and training: MD, University of North Dakota, Grand Forks; Pediatric residency, DeVos Children’s Hospital, Michigan State University, Grand Rapids; Pediatric endocrinology fellowship, University of Minnesota Department of Pediatrics Division of Endocrinology; MS in science clinical research, University of Minnesota

Research interests: Primary Investigator for the Type 1 Diabetes Exchange and an investigator on Juvenile Diabetes Research Foundation and National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) grants to study new artificial pancreas systems and studies evaluating new medications. Involved with the collaboration between International Diabetes Center and Melrose Institute to improve care for patients with eating disorders and diabetes.

Current research activities and funding:

PI, CGM Intervention in Teens and Young Adults (CITY): A Randomized Clinical Trial to Assess the Efficacy and Safety of Continuous Glucose Monitoring in Young Adults 14-
Co PI, Home Use of MD-Logic Automated Insulin Delivery System: Safety and Efficacy (Bergenstal/Phillips): This proposed research evaluates portable/wearable technologies to measure glucose levels and adjust delivery of insulin through a promising and novel automated closed-loop artificial pancreas (AP) system called Advanced Automated Insulin Delivery System. This research project will generate the data necessary to address the safety and reliability, of this AP system and prepare the way for a grant to study a larger number of patients with this optimized closed-loop system. The 2015-2016 NIDDK funding also allow us to develop a system to easily collect, aggregate and visualize glucose data from CGM devices a component that would greatly enhance patient understanding of the effectiveness and room for improvement of his or her closed loop system. Funder: NIDDK/ UC4DK108611.
Co-investigator: Efficacy and Safety of Faster-acting Insulin Aspart compared to NovoRapid® Both in Combination with Insulin Degludec in Children and Adolescents with Type 1 Diabetes (NOVO 4101) (Criego): A study about the efficacy and safety of faster-acting insulin Aspart compared to NovoRapid® both in combination with insulin Degludec in children and adolescents with type 1 diabetes. (Onset 7). Funder: Novo Nordisk.
Co-investigator, Hybrid Closed Loop Pivotal Trial in Type 1 Diabetes: A pivotal trial to prepare for commercialization of a Medtronic hybrid closed loop system test the safety and efficacy in adolescents and adults with T1D. Funder: Medtronic.
PI, JAEB Type 1 Diabetes Exchange: Grant to 67 clinics to establish a systematic registry of patients with T1D in clinics across the US for research purposes and to improve clinical care. Funder: Helmsley Trust.
PI, Multi-Center, Prospective, Observational Study of the TS (Threshold Suspend) Feature with a Sensor-Augmented Pump System in Pediatric Patients with Type 1 Diabetes: A study investigating the threshold suspend (low-glucose suspend) feature of the Medtronic 530G system in patients ages 2-15 years. Funder: Medtronic.